TD Cowen Maintains Annexon(ANNX.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)
Annexon To Present New Phase 2 ARCHER Data For ANX007 In Dry AMD Patients With Less Advanced GA At The American Academy Of Ophthalmology 2024 Meeting
Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14
Buy Rating Affirmed for Annexon Biosciences Amidst Promising Clinical Developments and Market Potential